Heindel v. Pfizer, Inc.

OPINION CHESLER, District Judge. This matter comes before the Court on the motion of Defendants, Pfizer, Inc., Pharmacia Corporation, the Monsanto Company, Searle & Co., and Merck & Co., Inc. for summary judgment. The Court has opted to adjudicate this motion on the papers, and renders this opinion without oral argument pursuant to Fed.R.Civ.P. 78. For the reasons set forth more fully below, Defendants’ motion is granted, and summary judgment entered dismissing Plaintiffs complaint. *366 I. IntROduction Plaintiffs in this matter are two consumers who suffer from pain associated with osteoarthritis and' other conditions. Both took prescription drugs to treat their conditions and both got relief from the drugs they took. Though neither plaintiff suffered any physical injury from either of the drugs at issue, both now claim that they are entitled to damages for the “economic injuries” they suffered due to Defendants’ failure to publicize the results of two clinical studies that revealed possible risks associated with the use of the drugs. Plaintiffs assert claims arising under the consumer fraud statutes of New Jersey or “other states,” claims for breach of implied warranty of merchantability, and claims for injunctive/equitable relief requiring Defendants to issue revised advertising statements, marketing materials, and product packaging. 1 For the reasons adduced more fully below, the Court finds that Plaintiffs’ claims lack merit under the laws of Pennsylvania. Moreover, the Court finds that since the Plaintiffs suffered no injury, there is no theory under which they are entitled to recover, and that Defendants are therefore entitled to summary judgment as to all claims. II. BACKGROUND A. Facts The Defendants in this matter manufactured and marketed two prescription pain medications which belong to a class of medications known as “non-steroidal anti-inflammatory drugs,” or “NSAIDs.” Pfizer, Inc., Pharmacia Corporation, Monsanto Co., and G.D. Searle & Co. (collectively the “Celebrex Defendants”) are (or were) the makers of Celebrex, while Yioxx is made by Merck & Co. (hereinafter “Merck”). Non-steroidal anti-inflammatory drugs reduce pain by blocking the body’s production of enzymes called cyclooxygenase, or “COX,” of which there are two forms: COX-1 and COX-2. Most traditional NSAIDs, (such as ibuprofen) work by blocking the COX-1 enzyme, which reduces pain but may lead to gastrointestinal perforations and bleeds. Celebrex and Vioxx, it is believed, block the COX-2 enzyme that triggers pain and inflamation while sparing the (COX-1) enzyme that helps maintain normal stomach lining. Both drugs are indicated for, inter alia, treating the signs symptoms of osteoarthritis, and rheumatoid arthritis, management of acute pain in adults, and treatment of primary dysmenorrhea. Plaintiffs Heindel and Kinmonth both suffer from pain associated with osteoarthritis. Both women, who are citizens of Pennsylvania, were treated by the same rheumatologist, Dr. Lawrence Leventhal, and both were prescribed (and took) traditional NSAIDs. Among other things, Heindel had survived esophageal cancer by having part of her stomach removed (and her stomach thereby raised); and Kin-month had a history of G.I. complications associated with her ingestion of other drugs used to treat her musculoskeletal aches and pains. These factors put both at risk for serious gastrointestinal side effects, including non-steroidal induced ulcers and ulcer complications because “people that are at risk for developing non-steroidal induced ulcers are: people over the age of 60, individuals with a history of G.I. bleed, [and] individuals with concomitant medical problems.” (Deposition of *367 Dr. Lawrence J. Leventhal (hereinafter Leventhal Dep.) at p. 7-8; 24-26.) Plaintiff Heindel Heindel first took Celebrex in February of 1999 when Dr. Leventhal provided her with samples of the drug. (Deposition of Dorothy Heindel (hereinafter “Heindel Dep.”) at 44-46; Leventhal Dep. at 14). Heindel responded favorably to Celebrex, which apparently gave her tremendous relief from her arthritis pain and other symptoms, and she did not experience any adverse side effects. (Heindel Dep. at 44-48). She continued to take Celebrex until July of 1999, when she read an article in a consumer newsletter that questioned the utility and safety of new drugs like Cele-brex. (Heindel Dep. at 60-63, 99-100). Dr. Leventhal told Heindel that Celebrex was the best treatment for her, and advised her to continue using it. (Heindel Dep. at 63-64; Leventhal Dep. at 18-19). Thereafter she resumed taking Celebrex, and apparently used it until February 2001, when, at Dr. Leventhal’s suggestion, she switched to Vioxx. (Heindel Dep. at 76-77; Leventhal Dep. at). Vioxx apparently caused her to experience stomach upset, and after a few months she switched back to Celebrex. (Heindel Dep. at 77; Leventhal Dep. at 55). 2 In February of 2002, Dr. Leventhal provided Heindel with another prescription drug, Bextra, to “see if it [was] better than Celebrex.” (Heindel Dep. At 80). Finding that it was not, Heindel switched back to Celebrex in November of 2002. (Heindel Dep. at 84). Heindel does not claim that she suffered ill effects from or was personally injured by Celebrex. It appears that, at least as of the filing of Defendants’ motion for summary judgment, she was still taking Cele-brex and planned to continue using it in the future. All of Heindel’s treatment took place in Pennsylvania, where Dr. Lev-enthal is located, where she lives, and where she purchased Celebrex and Vioxx. Plaintiff Kinmonth Kinmonth was first prescribed Celebrex in May or June of 1999. (Deposition of Jean Kinmonth (hereinafter “Kinmonth Dep.”) at 16-18, 95-96; Leventhal Dep. at 28). Some time in the spring of 2000, she switched to Vioxx, which Dr. Leventhal thought might provide her with a greater degree of relief. (Leventhal Dep. at 33-34). Though Vioxx initially provided Kin-month with more complete relief from her symptoms than Celebrex had, its efficacy declined over time, and she eventually switched back to Celebrex. Kinmonth does not claim that she suffered ill effects from or was personally injured by Celebrex or Vioxx. It appears that, at least as of the time of her deposition, she was still using Celebrex. (It is not clear whether she was still taking Vioxx or had any plans to do so.)All of Kinmonth’s treatment took place in Pennsylvania, where Dr. Leventhal is located, where she lives, and where she purchased Celebrex and Vioxx. B. Plaintiffs Claims Plaintiffs brought this consumer class action on behalf of the purchasers and users of Celebrex and Vioxx, claiming that they are entitled to recover economic damages they sustained due to Defendants’ “unconscionable marketing conduct.” Plaintiffs Brief (hereinafter “Pl.’s Br.”) at 1. They are pursuing claims under the New Jersey Consumer Fraud Act (Count *368 III) and for breach of implied warranty of merchantability (Count I). 3 Plaintiffs claim that Defendants knew, by 1998, that their “selective COX-2 inhibitors posed serious cardiovascular risks for anyone who took them,” but nonetheless made a marketing decision to “push these drugs to market on claimed improvements in gastrointestinal safety while downplaying their cardiovascular dangers.” Complaint at ¶¶ 23, 24. Plaintiffs contend that Defendants funded two significant clinical trials to justify their advertising claims and demonstrate that Celebrex and Vioxx had greater gastrointestinal safety than traditional NSAIDs-the Celecoxib Long-Term Arthritis Safety Study (“CLASS”) and the Vioxx Gastrointestinal Outcomes Research Study (“VIGOR”). Complaint at ¶ 25. The CLASS study compared gastrointestinal toxicity in arthritis patients taking Celebrex, ibuprofen, and dicofenac. It included patients with heart problems, who were allowed to take low prophylactic doses of aspirin to reduce the risk of adverse cardiovascular events. The VIGOR study-which compared gastrointestinal toxicity in patients taking VIOXX with those taking naproxen to treat arthritis excluded patients with heart problems. Complaint at ¶ 26, 27. Plaintiffs claim that Defendants’ attention to cardiac factors establishes their “secret acknowledgment of the likelihood cardiovascular events.” Id. at ¶ 28. Plaintiffs further allege that once the studies were concluded the Defendants tried to divert attention from cardiovascular risks by either not publishing cardiovascular data they had gathered or publishing partial information. (Presumably this allegation refers to publication in medical journals or other media traditionally used for the purpose of disseminating the results of clinical trials; it is not clear from the briefing.) The results of both studies were submitted to the FDA’s Arthritis Drugs Advisory Committee (“the Committee”) as part of requests to exempt Celebrex and Vioxx from gastrointestinal safety warning in their package inserts. Plaintiffs state that the Committee did not consider the cardiovascular safety of Celebrex, but they do not discuss whether this would have been a normal consideration given the scope of the exemption sought. They also state that, because patients in the VIGOR study suffered significantly more adverse cardiovascular events than those taking naproxen, the Committee suggested that “Merck add a warning to its package insert advising that Vioxx lacked the cardio-protective properties of traditional NSAIDs.” Id. at 34. However, it is not clear what Merck’s obligation was to warn of a protective quality that Vioxx did not have, as opposed to warning of side effects that may have affirmatively caused. Thereafter, Defendants “initiated extensive pre-release marketing campaigns” that emphasized Vioxx and Celebrex’s efficacy without gastrointestinal side effects. *369 This, Plaintiffs claim, was an attempt to “avoid negative publicity from the VIGOR report and the Committee’s decisions. Id. at 36. Subsequently, Celebrex and Vioxx were approved by the FDA and released for sale. According to the Plaintiffs, Defendants should have (at this point), used their exponential profits to fund further studies to quantify cardiovascular risks, but instead poured money into advertising campaigns that emphasized the gastrointestinal safety of the drugs. As a “result of’ these “misleadihg advertising campaigns, Celebrex and Vioxx were wildly successful.” Id. at 42-44. Persistent concern within the medical community about possible links between COX-2 inhibitors and increased blood clotting (with related incidence of cardiovascular events) eventually led to further research and study. In 2001 independent doctors from the Cleveland Clinic published a meta-analysis of the CLASS and VIGOR trials that concluded that COX-2 inhibitors posed an increased risk of adverse cardiovascular events compared to naproxen. Defendants did not modify their package inserts to reflect the results of the Cleveland Clinic study. Though Plaintiffs contend that the FDA sent both Defendants cautionary letters reflecting its concern about their failure to include warn of cardiovascular side effects in direet-to-con-sumer advertising, it is far from clear that the FDA’s letters addressed this issue. Vioxx and Celebrex have not been taken off the market, and remain popular treatments for osteoarthritis and other types of pain. Plaintiffs admit that they are not pursuing any claims for physical injury, either for themselves or for the two sub-classes they seek to represent. Rather, their claims are based on the economic injury that Defendants’ marketing practices have allegedly caused them. (Pl.’s Br. at 2). Specifically, they posit that Defendants’ “uniform failure to disclose known cardiovascular risks associated with Celebrex and Vioxx caused consumers to pay artificially inflated prices for them.” Id. Plaintiffs seek to recover some or all of the purchase price consumers paid for these drugs. PL’s Br. at 4-5. Though this suit arises out of economic injuries allegedly suffered by the Plaintiffs, both Heindel and Kinmonth denied, when deposed, that they had suffered economic harm. Both plaintiffs also testified that they took Celebrex and Vioxx at the suggestion of their physicians, and did not rely on advertising or marketing materials created or distributed by Defendants. III. SUMMARY Judgment Standard Summary judgment is appropriate only if all of the probative materials in the record, viewed in the light most favorable to the non-moving party, demonstrate that there is no genuine issue of material fact and that the movant is entitled to judgment as a matter of law. Fed.R.Civ.P.56(c); Brooks v. Kyler, 204 F.3d 102, 105, n. 5 (3d Cir.2000); Celotex v. Catrett, 477 U.S. 317, 330, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986) Todaro v. Bowman, 872 F.2d 43, 46 (3d Cir.1989). An issue is “genuine” if a reasonable jury could possibly hold in the non-movant’s favor with regard to that issue. See Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 247-48, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). A fact is “material” if it influences the outcome under the applicable law. Anderson, 477 U.S. at 248, 106 S.Ct. 2505. The moving party bears the initial burden of demonstrating either (1) that there is no genuine issue of fact and that, as a matter of law, the moving party must prevail, or (2) that the non-moving party has not shown facts relating to an essential element of the issue for which he bears the *370 burden of proof. Celotex, 477 U.S. at 331, 106 S.Ct. 2548. Once either showing is made, the burden shifts to the non-moving party, who must demonstrate facts which support each element of the for which he bears the burden, and establish the existence of genuine issues of material fact. Id. To satisfy this burden, the non-moving party “may not rest on mere allegations or denial of his pleading.” Fed.R.Civ.P. 56(e). Rather, he must produce sufficient evidence from which a reasonable jury might find in his favor, and may not simply create some metaphysical doubt as to material facts. Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574, 106 S.Ct. 1348, 89 L.Ed.2d 538 (1986). IV. ChoiCe of Law The parties disagree as to which state’s law this Court should apply in considering Plaintiffs claims. Plaintiffs claim that, because Defendants have failed to establish specific conflicts between the laws of New Jersey and Pennsylvania, the laws of this forum (New Jersey) should apply. They also contend that the objectives underlying the consumer warranty laws of New Jersey and Pennsylvania are identical, thus requiring the application of New Jersey law to Plaintiffs claims. Turning to the governmental interest analysis, Plaintiffs argue that New Jersey has the greatest interest in having its law govern these claims because (1) the New Jersey legislature has expressed a specific intent to protect the citizens of other states from the deceptive practices of businesses located within its boundaries (even if some aspect of the transaction took place outside New Jersey); (2) many of the corporate decisions and actions that form the basis for Plaintiffs claims including the development, production, and marketing of Cele-brex and Vioxx-took place in New Jersey; and (3) because “Defendants have other significant contacts with New Jersey that give this state an express interest in having its laws apply to their conduct.” Among the contacts mentioned are Defendants’ large corporate presence in the state, the considerable number of people it employs, the tax breaks it receives from New Jersey, and the number of lawsuits (unrelated to this one) filed by Defendants in New Jersey courts. The Defendants contend, for essentially the same reasons, that Pennsylvania law should apply. They stress that both Plaintiffs live in Pennsylvania; that the conduct alleged occurred in Pennsylvania; and that the alleged financial injuries were suffered in Pennsylvania. All Defendants argue that the mere fact of a corporate presence (a minimum threshold which some of these defendants do not even meet, since only one of the four Celebrex Defendants has headquarters in New Jersey) does not give New Jersey an interest in the adjudication of these claims which overrides that of the Plaintiffs’ home state. Thus, they argue, New Jersey has neither sufficient contacts with this litigation nor the requisite governmental interest in having its laws applied. Federal courts sitting in diversity must apply the choice of law rules of the forum in which they sit. Klaxon Co. v. Stentor Electric Manufacturing Co., 313 U.S. 487, 496, 61 S.Ct. 1020, 85 L.Ed. 1477 (1941); Erie R. Co. v. Tompkins, 304 U.S. 64, 78, 58 S.Ct. 817, 82 L.Ed. 1188 (1938). Accordingly, New Jersey’s choice of law rules govern this Court’s analysis. Chin v. Chrysler Corp., 182 F.R.D. 448, 457 (D.N.J.1998). New Jersey’s rule “applies a flexible ‘governmental interest’ standard, which requires application of the law of the state with the greatest interest in resolving the particular issue that is raised in the underlying litigation.” Gantes v. Kason, 145 N.J. 478, 484, 679 A.2d 106 (1996). *371 The initial prong of a government interest analysis entails an inquiry into whether there is an actual conflict between the laws of the respective states, a determination that is made on an issue-by-issue basis. Gantes, 145 N.J. at 484, 679 A.2d 106; see also Veazey v. Doremus, 103 N.J. 244, 248, 510 A.2d 1187 (1986). Hence, the Court’s inquiry addresses potential conflicts between (1) the laws pertaining to implied warranty of merchantability; and (2) the consumer fraud statutes of New Jersey and Pennsylvania. A. Whether a Conflict Exists In addition to not agreeing on which state’s laws should apply, the parties do not agree as to how the Court should go about making such a determination. Plaintiffs, citing Boyes v. Greenwich Boat Works, 27 F.Supp.2d 543, 547 (D.N.J.1998), contend that “[w]here the parties fail to point out or establish any difference in the laws of the various jurisdictions involved in a particular case, its proper for the court to apply the law of the forum.” They then point out that, while Defendants may have identified areas of potential differences between the laws of New Jersey and Pennsylvania, these differences are immaterial because the underlying policies of both laws are the same. This approach assumes that the initial determination as to whether a conflict exists should be based on whether the policies underlying the respective laws differ. However, it is clear that under the governmental interest test a court must “first determine whether a conflict exists between the laws of the interested states,” Veazey v. Doremus, 103 N.J. 244, 510 A.2d 1187 (1986) and, if the court finds a conflict, then determine “the state with the greatest interest in governing the particular issue.” Veazey, 103 N.J. at 251, 510 A.2d 1187 (emphasis added). To do this, the court must “identify the governmental policies underlying the law of each state and how these policies are affected by each state’s contacts to the litigation and the parties.” Id. Hence, the Court should turn to an evaluation of the underlying policies only after determining that there indeed exists a conflict between the laws of the two states. None of the parties have conducted a conflict analysis that follows this model, perhaps because aspects of each state’s laws are unsettled as to one or another of the claims presented. Complicating matters is the somewhat novel application of implied warranty and consumer fraud remedies to claims that are predicated only on “economic injury.” Nonetheless, the Court finds that the parties have indeed pointed out differences between the laws of New Jersey and Pennsylvania, and thus proceeds with the analysis. 1. Breach of Implied Warranty of Merchantability Defendants argue that Pennsylvania law conflicts with New Jersey law in that, under Pennsylvania law, a claim for breach of implied warranty of merchantability may not be maintained against a seller of prescription drugs. The implied warranty of merchantability, “as described in the Uniform Commercial Code (“U.C.C.”) and adopted by Pennsylvania, is ‘a warranty that the goods will pass without objection in the trade and are fit for the ordinary purposes for which such goods are used.’ ” Davenport v. Medtronic, Inc., 302 F.Supp.2d 419 (E.D.Pa.2004); 13 Pa.C.S. § 2314. In order to prevail under Pennsylvania law on a claim for breach of implied warranty, a plaintiff must show that the product was “defective.” Thomas v. Carter-Wallace Inc., 1994 WL 904463, 27 Pa. D & C. 4th 146, 149 (Pa.Com.Pl.1994) (citing Dambacher by Dambacher v. Mallis, 336 Pa.Super. 22, 485 A.2d 408 (1984)), aff'd, 449 Pa.Super. 711, 673 A.2d 412 *372 (1995)(finding that “a breach of implied warranty of merchantability theory in Pennsylvania states that a merchant is ‘only liable for harm caused by a defect in their product.’ ”); Altronics of Bethlehem, Inc. v. Repco, Inc., 957 F.2d 1102, 1105 (3d Cir.1992) (an implied warranty of merchantability plaintiff must establish, inter alia, ‘that the product malfunctioned.’) Grant v. Bridgestone Firestone, Inc. 2002 WL 372941 (Pa.Com.Pl. Jan. 10, 2002). New Jersey’s uniform commercial code provides, as pertinent, that “[gjoods to be merchantable must be at least such as ... are fit for the ordinary purposes for which such goods are used.” The exact showing required to establish a breach of implied warranty of merchantability claim is somewhat more amorphous in New Jersey, and the New Jersey courts have used various terms to describe it. See Yost v. General Motors Corp., 651 F.Supp. 656, 658 (D.N.J.1986) (“[d]amage is a necessary element of ... breach of warranty” claims); Hollinger v. Shoppers Paradise of New Jersey, Inc., 134 N.J.Super. 328, 332, 340 A.2d 687 (1975), (“Pliability is established if the evidence shows that the product was not reasonably fit for the ordinary purposes for which it was sold and [the] defect proximately caused injury to the ultimate consumer.”). See also Kaspirowitz v. Scbering Corp., 70 N.J.Super. 397, 403-04, 175 A.2d 658 (1961) (finding that, where a prescription dandruff shampoo caused the plaintiff to have an adverse reaction “we are not dealing with a Defective product on the sale of which a claim of breach of an implied warranty of merchantability must necessarily rest.”); Adams v. Peter Tramontin Motor Sales, Inc., 42 N.J.Super. 313, 325, 126 A.2d 358 (1956) (finding that product at issue “met the test of merchantability,” where “[i]t was reasonably suitable for ordinary use ... [and] possessed no remarkable defect.”). 4 (a) Whether a Claim for Breach of Implied Warranty can be Maintained Against a Manufacturer of Prescription Drugs Defendants contend- and Plaintiffs concede Pennsylvania law bars claims for breach of implied warranty against a manufacturer of prescription drugs. Defendants rely on Makripodis v. Merrell-Dow Pharmaceuticals, Inc., 361 Pa.Super. 589, 593, 523 A.2d 374 (1987) (and its progeny), which holds that the very nature of prescription drugs themselves precludes the imposition of a warrant of fitness for “ordinary purposes,” as each individual for whom they are prescribed is a unique organism who must be examined by a physician who is aware of the nature of the patient’s condition as well as the medical history of the patient. The reasoning in Makripodis, which involved a claim against a pharmacist, has subsequently been applied to bar breach of implied warranty claims against pharmaceutical manufacturers and makers of medical devices. See Luke v. Am. Home Prods. Corp., 1998 WL 1781624 at *6 (Pa.Com.Pl.1998); Murray v. Synthes (U.S.A.), Inc., 1999 WL 672937 at *9 (E.D.Pa.1999). See also Hahn v. Richter, 543 Pa. 558, 673 A.2d 888, 891 (1996) (holding that “where the adequacy of warnings associated with prescription drugs is at issue, the failure of the manufacturer to exercise reasonable care to warn of dangers, i.e., the manufacturer’s negligence, is the only recognized basis of liability.”) It is uncontested that New Jersey law contemplates no such limitation on breach *373 of implied warranty claims against prescription drug manufacturers. Accordingly, the Court finds that there is an actual conflict between the laws of New Jersey and Pennsylvania as they pertain to this issue, and proceeds to the next step of the analysis. 2. Consumer Fraud Claims Plaintiffs assert (on behalf of the payer sub-class) a claim arising under the New Jersey Consumer Fraud Act (“NJCFA”), N.J.S.A. 56:8-1(c) and “other states’ consumer protection statutes.” Compl. ¶¶ 93-100. Defendants argue that the Plaintiffs consumer fraud claims should be governed by Pennsylvania’s Unfair Trade Practices and Consumer Protection Law (“UTPCPL”), 73 P.S. § 201-2 et seq. The UTPCPL provides, as pertinent, that Any person who purchases or leases goods or services primarily for personal, family or household purposes and thereby suffers any ascertainable loss of money or property, real or personal, as a result of the use or employment by any person of a method, act or practice declared unlawful by section 3 of this act [73 P.S. § 201-3], may bring a private action to recover actual damages or one hundred dollars ($100), whichever is greater. The court may, in its discretion, award up to three times the actual damages sustained, but not less than one hundred dollars, and may provide such additional relief as it deems necessary or proper. The NJCFA provides, as pertinent, that The act, use or employment by any person of any unconscionable commercial practice, deception, fraud, false pretense, false promise, misrepresentation, or the knowing, concealment, suppression, or omission of any material fact with intent that others rely upon such concealment, suppression or omission, in connection with the sale or advertisement of any merchandise ... or with the subsequent performance of such person as aforesaid, whether or not any person has been damaged thereby, is declared to be an unlawful practice. N.J.S.A. 56:8-2. As Defendants point out, the private remedy provisions of both statutes require a plaintiff to have suffered an ascertainable loss. See Weinberg v. Sprint Corp., 173 N.J. 233, 801 A.2d 281 (2002) (holding that, in order “to have standing under the Act a private party must plead a claim of ascertainable loss that is capable of surviving a motion for summary judgment.”); Weinberg v. Sun Co., Inc., 565 Pa. 612, 618, 777 A.2d 442 (2001) (“[t]he statute clearly requires, in a private action, that a plaintiff suffer an ascertainable loss as a result of the defendant’s prohibited action.”)(emphasis in original). However, the New Jersey and Pennsylvania laws differ in several important respects. First, reliance is an element of claims arising under the UTPCPL, but not the NJCFA. The Pennsylvania Supreme Court “has held expressly that successful prosecution of a private cause of action under the UTPCPL is dependant upon pleading and proof by the plaintiff that he or she suffered an ascertainable loss ‘as a result of the defendant’s prohibited conduct. The Court has interpreted this language to mean that a plaintiff must establish his specific reliance on some conduct or representation by the defendant that caused him to incur the loss in question.” Sexton v. PNC Bank, 792 A.2d 602, 607 (2002) (citation omitted). The New Jersey statute, on the other hand, “requires only a causal nexus between the ‘method, act, or practice declared unlawful’ and the con *374 sumer’s ‘ascertainable loss.’ The [New Jersey] Supreme Court has taken pains to point out that this element is significantly distinct from the requirement of reliance in a common law fraud claim. A defendant who violates the Act because of an unlawful ‘method, act, or practice’ that results from an omission of a material fact with the ‘intent that others rely upon such concealment, suppression, or omission,’... is liable for [such] representations whether ‘any person has in fact been misled, deceived, or damaged thereby.’ ” Varacallo v. Mass. Mutual Life Insurance Co., 332 N.J.Super. 31, 48, 752 A.2d 807 (2000) (internal citations omitted). Second, the New Jersey and Pennsylvania laws have different damages and attorney’s fees provisions. In “New Jersey the assessment of treble damages and attorney’s fees is mandatory when a violation of the Consumer Fraud Act has been proved.” Huffmaster v. Robinson, 221 N.J.Super. 315, 320, 534 A.2d 435 (1986) (citing Skeer v. EMK Motors, Inc., 187 N.J.Super. 465, 455 A.2d 508 (1982)). In Pennsylvania those assessments are discretionary. See Pennsylvania Unfair Competition and Practice Act, 73 Pa.Cons. Stat. § 201-9.2. Finally, under Pennsylvania law, the learned intermediary doctrine may bar Plaintiff’s UTPCPL claims for reasons similar to those discussed above in relation to the implied warranty claims. Pennsylvania courts that have addressed this issue in the context of claims brought against a maker of prescription drugs have ruled that, “[t]here can be no cause of action based on Defendants’ alleged omission because Defendants had no duty to disclose any information directly to Plaintiff. Further, to permit a cause of action under the UTPCPL in this case would effectively make a drug manufacturer the absolute guarantor of the anticipated results and effects of a prescription drug.” Luke v. American Home Products Corp., 1998 WL 1781624, * 8 (Pa.Com.Pl.1998). Because New Jersey Courts have not articulated such a doctrinal obstacle to recovery under the state’s consumer fraud act, the laws of the states are in conflict in this respect as well. Based on the foregoing, the Court is satisfied that there is an actual conflict between the UTPCPL and the NJCFA. Accordingly, the Court proceeds to the next stage of the analysis. B. Underlying Governmental Policies and their Relationship to the Parties’ Contacts I. Having determined that there is an actual conflict between the laws of Pennsylvania and New Jersey, the “next step is to identify the governmental policies underlying the law of each state and how those policies are affected by each state’s contacts to the litigation and to the parties.” D'Ag ostino v. Johnson & Johnson, Inc., 133 N.J. 516, 523, 628 A.2d 305 (1993) (citing Veazey, 103 N.J. 244, 510 A.2d 1187 (1986) (citations omitted)). With respect to both implied warranties of merchantability and consumer fraud statutes, New Jersey and Pennsylvania have similar (and in some respects identical) policy objectives. In both states, the implied warranty of merchantability is “designed to protect the buyer of goods from bearing the burden of loss where merchandise, though not violating a promise expressly guaranteed, does not conform to the normal commercial standards or meet the buyer’s particular purpose, a condition upon which he had the right to rely.” Vlases v. Montgomery Ward. & Co., 377 F.2d 846, 849 (3d Cir.1967) (applying Pennsylvania law). Moreover, the enforcement of implied warranties of mer *375 chantability is intended to address potential imbalances in the bargaining position of and knowledge possessed by respective parties to a transaction, and reduce the risk that in the absence of an express warranty the party in the greater bargaining position will be able to sell a substandard product with impunity. Likewise, the consumer fraud statutes of both states are premised on similar legislative goals. The UTPCPL’s “‘underlying foundation is fraud prevention,’ ” Weinberg v. Sun Company, Inc., 565 Pa. 612, 618, 777 A.2d 442 (2001), and in passing it the legislature intended to protect consumers against unfair or deceptive business practices, see Pirozzi v. Penske Olds-Cadillac-GMC, Inc., 413 Pa.Super. 308, 605 A.2d 373, (1992) appeal denied, 532 Pa. 665, 616 A.2d 985, and place the seller and consumer on more equal terms, see Com. by Packel v. Ziomek, 145 Pa.Cmwlth. 675, 352 A.2d 235 (1976). The New Jersey statute was conceived to protect the consumer against imposition and loss as a result of fraud and fraudulent practices by sellers of goods and services. See Scibek v. Longette 339 N.J.Super. 72, 770 A.2d 1242 (2001). Its three main purposes are generally described as (1) compensating the victim for his or her actual loss; (2) punishing the wrongdoer through the award of treble damages; and (3) attracting competent counsel to counteract the “community scourge” of fraud by providing an incentive for an attorney to take a case involving a minor loss to the individual. See Lettenmaier v. Lube Connection, Inc., 162 N.J. 134, 741 A.2d 591 (1999). II. The next stage of the choice of law inquiry examines the relationship of each state’s contacts to the policies underlying the respective laws. “If a state’s contacts are not related to the policies underlying its law, then that state does not possess an interest in having its law apply. Consequently, the qualitative, not the quantitative, nature of a state’s contacts ultimately determines whether its law should apply.” D’Agostino, 133 N.J. at 523, 628 A.2d 305 (citing Veazey, 103 N.J. 244, 510 A.2d 1187 (1986) (citations omitted)). The parties’ contacts are as follows. Plaintiffs Heindel and Kinmonth live in Pennsylvania, are residents of Pennsylvania, and were treated by their physicians in Pennsylvania. They were prescribed- and purchased-Celebrex and Vioxx in Pennsylvania. To the extent that they saw advertising about Celebrex or Vioxx, or read any package inserts, warnings, or informational newsletters, they appear to have done so in Pennsylvania. (See Merck’s 56.1 Statement at ¶¶ 16-26; Cele-brex Def.’s 56.1 Statement at ¶¶ 7-54). Moreover, their physicians were based in, and worked from offices or hospitals in Pennsylvania. With respect to the Defendants, Plaintiffs contend that Merck’s pharmaceutical business is conducted through its divisional headquarters located in New Jersey. (Pl.’s 56.1 Statement at ¶ 12). Furthermore, they claim that a vast majority of Merck’s corporate functions, including those related to Vioxx, are located in New Jersey; that Merck provided the source information for the VIGOR trial from its New Jersey offices; that New Jersey residents participated in the VIGOR study; and that Merck conducted various public relations functions from its New Jersey headquarters. (Id.). However, the record establishes that Merck employees stationed in Pennsylvania had responsibility for much of the interaction with the FDA regarding Vioxx. Declaration of Wilfred Coronato (“Coronato Dec.”) at Exh. B, ¶ 10. The department of Merck Research Laboratories responsible for collecting adverse events and reporting them to the *376 FDA is also located in Pennsylvania, as is the headquarters of Merck’s United States Human Health Division, which markets Vioxx in the U.S. (Id. at ¶¶ 11, 12). The head of the U.S. Human Health Division had his primary office in Pennsylvania during the time period relevant to this lawsuit, and his subordinate directly responsible for marketing Vioxx was also in Pennsylvania. (Id. at ¶¶ 13). The groups within the U.S. Human Health division in charge of training its U.S.-based professional representatives, and which have responsibility for advertising Vioxx in the U.S., are based in Pennsylvania. (Id. at ¶¶ 14, 15). Finally, the committee at Merck Research Laboratories that is responsible for the drafting and editing of the Product Circular (containing warnings, precautions, and other information concerning adverse effects and contraindications) is comprised of employees located in both Pennsylvania and New Jersey. (Id. at ¶ 9). With respect to the Celebrex Defendants, Plaintiffs contend that Pfizer conducts corporate functions (such as those related to the development, distribution, manufacture, research, and sale of Cele-brex) in New Jersey; that Pfizer broadcast and published Celebrex ads in New Jersey; and that Pfizer sent “Dear Doctor” letters to New Jersey physicians downplaying the cardiovascular risks of Celebrex. They also contend that Phar-macia maintains headquarters in New Jersey and hired a marketing consultant with a New Jersey based office to handle the global promotion of Celebrex. However, the record establishes that both Plaintiffs started taking Celebrex in 1999, when the drug was manufactured and marketed by corporate predecessors of Pfizer that were neither incorporated nor headquartered in New Jersey. (Celebrex Defendant’s Brief in Support of it’s Motion for Summary Judgment (hereinafter Celebrex Def.’s Br.) at 17). Celebrex was developed by Searle, a Delaware Corporation with its principal place of business in Illinois. (Compl. at ¶ 10). In June of 1998 Searle, then a subsidiary of the Missouri-based Monsanto, submitted the marketing application for Celebrex to the FDA, which granted its approval in December of 1998. (Celebrex Def.’s Br. at 17). Celebrex was eo-promot-ed from the time of FDA marketing approval by Searle and Pfizer, a Delaware corporation with its principal place of business in New York, pursuant to a co-promotion agreement between Pfizer and Searle. (Id.) In March of 2000, Searle’s parent corporation, Monsanto, merged with Pharmacia & Upjohn to form Phar-macia. According to Defendants, promotional activities were coordinated out of Pharmacia’s headquarters in New Jersey and Pfizer’s headquarters in New York for some period of time after the March 2000 merger, but the Searle regulatory personnel responsible for Celebrex remained in Illinois. (Id.) In April of 2003, Pfizer acquired Pharmacia, and Celebrex promotional activities are apparently now coordinated out of Pfizer’s headquarters in New York. Celebrex is, and was at all relevant times, manufactured in Puerto Rico. (Id.) Hence, only one of the four Celebrex Defendants (Pharmacia) has headquarters in New Jersey. Finally, Plaintiffs list a number of ancillary contacts that both companies have with the state of New Jersey, such as the length of their corporate presences, the number of people they employ, the tax breaks and businesses incentives they enjoy, and their availment of the courts of this jurisdiction over the course of a year. In short, it appears that Defendants’ contacts with New Jersey can be summarized as (1) the presence of Merck’s principal place of business in the state (though the division that markets and advertises *377 Vioxx is headquartered in Pennsylvania); and (2) the presence of Pharmacia’s principal place of business in the state between March of 2003 and April of 2003 (though many marketing, advertising, and regulatory functions appear to have been conducted elsewhere). 5 III. At the outset, it bears noting that the parties have engaged in assiduous parsing of particular marketing and advertising functions and where they took place. While some corporate and marketing functions clearly took place in New Jersey, it appears that just as many others took place in other states. Generally, courts weighing the competing interests of the state where a corporation is domiciled against those of the consumer’s home state do not engage in a microanalysis of specific marketing and promotional practices and their relative significance. This is not to say that courts do not consider where marketing or advertising originated, especially where (as here) the underlying allegations are based on fraud or misrepresentation, as to which advertising and marketing are of course relevant. However, examining in depth which individual functions or phases in the marketing and advertising process are more significant than others would constitute a lengthy and ultimately unproductive digression. With respect to Merck, the marketing and promotional activities that occurred in Pennsylvania appear to outweigh or at the very least equal in significance those that took place in New Jersey. The case for considering the marketing and promotional activities of the Celebrex Defendants is even less compelling, as it appears that there was only a brief period during which these activities took place in New Jersey, and that at all other times marketing and promotion primarily took place elsewhere. In short, this Court finds that the performance of various marketing and promotional activities in New Jersey is not a compelling interest as it pertains to either the warranty claim or the consumer fraud claim. Hence, as is often the case in conflicts analysis, the determination of which state’s law bears the more compelling relationship to the underlying policies turns on the relative interests of the corporation’s home state' and the consumer’s home state. The facts of this case and the nature of the Plaintiffs claim present what have been called “often difficult issues with respect to conduct regulating laws [which] include, but are by no means limited to ... the scope and impact of the learned intermediary doctrine, and the rules governing disclosure in the advertising of ethical pharmaceuticals.” In re Rezulin Products Liability Litigation, 210 F.R.D. 61, 70 (S.D.N.Y.2002). To be certain, New Jersey has a interest in governing the conduct of its corporate citizens and encouraging truthful marketing and advertising of products. However, with respect to both the warranty and consumer fraud claims, Pennsylvania has a competing interest in ensuring that its own citizens “are compensated for their injuries, that the standards its [sic] sets for product sales within its borders are complied with, and that the rules it establishes to govern physician and pharmacist are upheld.” Id. at 70-71. These interests are not outweighed by New Jersey’s interest in regulating the conduct of its pharmaceutical companies. The “particular configuration of the state interests to be balanced, and the relative weight of those interests as dictat *378 ed by the relevant contacts with the par•ties” require that “the deterrence interest of New Jersey as the domicile and locus of the defendant manufacturer must yield in this case to the compensation interest” of Pennsylvania. See Gantes v. Kason Corp., 145 N.J. 478, 496-97, 679 A.2d 106 (1996). Here, the only real contacts that Defendants had with New Jersey — the state with the deterrent interest — are somewhat attenuated. Moreover, since Celebrex and Vioxx were marketed, advertised, distributed, prescribed, and purchased in Pennsylvania, that state has both a deterrent interest in and a compensation interest. Other factors require this outcome. First, while a number of New Jersey courts have chosen to apply the NJCFA over the consumer protection law of another state, finding that New Jersey law “should be construed liberally in favor of protecting consumers,” Levin v. Lewis, 179 N.J.Super. 193, 200, 431 A.2d 157 (1981) and its mandatory treble damages and fee provisions provide a heightened level of protection, it is important to distinguish the particular transactions at issue in those cases from the one involved here. Obviously, this case does not involve the sale of a boat, a car, or a house. See Boyes v. Greenwich Boat Works, Inc., 27 F.Supp.2d 543 (D.N.J.1998); Huffmaster v. Robinson, 221 N.J.Super. 315, 534 A.2d 435 (1986); Gennari v. Weichert, 148 N.J. 582, 691 A.2d 350 (1997). The “transaction” at issue here is Plaintiffs’ ingestion of prescription medicines that were prescribed, purchased, paid for, and allegedly damaged the Plaintiffs in their home state. None of these things could have occurred without the involvement of a physician. In Incollingo v. Ewing, 444 Pa. 263, 444 Pa. 299, 282 A.2d 206 (1971), the Pennsylvania Supreme Court adopted the learned intermediary doctrine, which, among other things, circumscribes the liability of prescription drug manufacturers. Though originally the basis for eliminating the imposition of strict products liability against drug manufacturers, the rule has evolved to apply to other causes of action, including implied warranty and consumer fraud. The learned intermediary doctrine clearly reflects the determination by the Pennsylvania courts to preserve the primacy of the physician’s role in making treatment decisions for Pennsylvania patients-including the making of informed choices about prescription drugs. 6 In light of this, the most important aspects of the transaction underlying this lawsuit are the decisions of the physician and the relationship between doctor and patient, all of which occurred in Pennsylvania. New Jersey’s consumer protection statute arguably offers greater protection to the consumer. However, the plaintiffs in this matter are not residents of New Jersey, and given the competing interests of Pennsylvania, New Jersey does not have a “compelling reason ... to extend to such non-domiciliary plaintiffs the benefit of [its] decisional law.” Deemer v. Silk City Textile Mach. Co., 193 N.J.Super. 643, 475 A.2d 648 (1984). Consequently, the laws of Pennsylvania must govern. IV. Disoussion Having determined that Pennsylvania law governs both the breach of implied warranty and consumer fraud claims, the Court turns to the merits of those claims. *379 The Court will first address whether Plaintiffs “fraud on the market” theory is viable, and then whether the learned intermediary doctrine precludes the breach of implied warranty and consumer fraud claims. A. Plaintiffs’ “Fraud on the Market” Theory As a preliminary matter, the Court turns to Plaintiffs’ problematic assertion that their claims “challenge Defendants’ intentional failure to disclose the known cardiovascular risks of Celebrex and Yioxx to consumers and seek to recover some or all of the purchase price consumers paid for these drugs.” Complaint at ¶¶ 2, 35-36, 44, 51, 59, 63-67. Their claim for economic damages caused by the payment of allegedly inflated prices for Defendants’ products is based upon a vaguely articulated “fraud on the market” rationale. Because the “fraud on the market” theory is untenable as to both remaining claims, the Court will briefly address this issue at the outset. 1. Implied Warranty of Merchantability Clearly, neither Plaintiff was personally injured by Celebrex or Yioxx. They do not claim to have suffered any bodily harm and, accordingly, have withdrawn their product liability and medical monitoring claims. This presents an issue which is at the core of this case, namely, if there is no “defect” at issue, and the drugs themselves caused no harm, how were Heindel and Kinmonth injured? Their apparent explanation is that, given the potential cardiovascular side effects, they simply paid too much for the drugs. By asserting economic loss, Plaintiffs “seek to move the suit out of the tort domain and into that of contract,” because, allegedly, the drugs were not as they were “described and thus [were] not merchantable, a warranty theory.” See In re Bridgestone/Firestone, Inc., 288 F.3d 1012, 1017 (7th Cir.2002). First, this ‘shift’ into the realm of contract is problematic because “if tort law fully compensates those who are physically injured, then any recoveries by those whose products function properly means excess compensation.” Id. at 1017. Moreover, breach of implied warranty claims are not intended to address hypothetical economic loss; they are meant to compensate a buyer who has not gotten the benefit of her bargain because the product in question does not meet generally accepted standards or disappoints consumer expectations. These plaintiffs would be hard pressed to claim that they did not get what they paid for. Indeed, the record unequivocally establishes that Celebrex and Vioxx were effective treatments for Heindel and Kinmonth’s arthritis pain, and that both benefitted significantly from its use. Kin-month testified that she found Vioxx more effective than other, non-narcotic medicines that she had used in the past, and that the relief it gave her from arthritis pain allowed her to function better and do things that had been made difficult by her condition, such as preparing food and lifting things. (Coronato Decl. at Exh. D, (hereinafter Kinmonth Dep.) p. 64-70). Kinmonth also testified that Celebrex gave her relief from her symptoms, and she reported to her doctor that she liked its results. Kinmonth Dep. at p. 119; Leven-thal Dep. at p. 39-40. Likewise, Heindel “liked” the results she got from Celebrex, found it more effective than several other non-narcotic drugs she had tried, and even told her doctor that it was “as close to a panacea as is likely to be found.” (Heindel Dep. at 46-48; Leventhal Dep. at 15-16). Both plaintiffs continued to use Vioxx and Celebrex after the complaint was filed in this lawsuit, and were taking it as of the time they were deposed. *380 Despite the irrefutable evidence that Plaintiffs got the effective arthritis remedy that they bargained for, they seek to recover “some or all of the purchase price” paid for Celebrex and Vioxx. Complaint at ¶¶ 2, 35-36. Clearly, the Plaintiffs would not be entitled to recover all of the purchase price of the drugs; this would amount to a claim for restitution, to which they are obviously not entitled. As the court in In re Rezulin Products Liability Litigation, 210 F.R.D. 61, 68 (S.D.N.Y.2002) (a case that, like this one, involved claims for purely economic losses alleged by otherwise unharmed consumers of a prescription drug) found: In order to obtain restitution for the purchase price of [the drug], plaintiffs and class members would be obliged, at least in many jurisdictions, to prove some kind of harm. In other words, although theories presumably could differ, they would have to establish that ... that the defendants’ retention of the price they paid for the drug would be unjust, that the value of the drug given its allegedly concealed defects was less than the purchase price, or some other variation that would warrant the transfer of money from the defendants to them. Plaintiffs contention that everyone who took Rezulin sustained an ascertainable loss presumes that Rezulin was worthless. But that is not a defensible position. Even Plaintiffs experts acknowledge that Rezulin was enormously beneficial to many patients. Those patients got their money’s worth and suffered no economic injury. In re Rezulin Products Liability Litigation, 210 F.R.D. 61, 68 (S.D.N.Y.2002) (emphasis supplied). This Court agrees with the above conclusions. Finding no other theory under which they would be entitled to reimbursement for some or all of the purchase price of the arthritis medicine whose benefits they clearly enjoyed, Plaintiffs attempt to explain away this deficiency with their “price inflation” or “fraud on the market” theory. In this context, though, such a theory is patently absurd. It depends on the totally implausible predicate that, had some adverse information about side effects derived from the VIGOR and CLASS studies been more widely disseminated, the Plaintiffs would have paid less for Ce-lebrex and Vioxx. However, (at the risk of stating the obvious) there is no prescription drug “market,” at least as that term is understood in the securities context. There, a “perfect market” or “efficient market” is assumed, and adverse information is expected to be quickly absorbed by the market, thus causing the price of the stock or commodity at issue to fluctuate. But the only “market” for a prescription drug is the potential group of patients who will be prescribed it by them physician, and if the side effects of the drug make it overly risky to ingest, the doctor will either not prescribe it or the patients will decide not to take it. The suggestion that consumers might be inclined to take a drug with certain side affects if they could pay less for it, or that drugs with certain side effects should cost less, defies both reality and common sense. It is also out of place in this lawsuit, where it is clear that neither plaintiff suffered any adverse effects. In short, the decision to take a particular drug is a medical one, not one based on an comparative analysis of risk versus price. 2. Consumer Fraud For the same reasons, the fraud on the market theory is flawed with respect to Plaintiffs consumer fraud claims. Moreover, in Weinberg v. Sun Co., 565 Pa. 612, 777 A.2d 442 (2001) the Pennsylvania Supreme Court explicitly rejected an attempt by a class of consumers to employ the *381 fraud on the market theory in a case arising under the UTPCPL. The plaintiffs in Weinberg were consumers of high octane gasoline who claimed that “the [defendants’] false marketing campaign increased the demand for Ultra(R) gasoline, raising the price for all consumers.” The Court found that [t]here is no authority which would permit a private plaintiff to pursue an advertiser because an advertisement might deceive members of the audience and might influence a purchasing decision when the plaintiff himself was neither deceived nor influenced ... Nothing in the legislative history suggest that the legislature ever intended the statutory language directed against consumer fraud to do away with the traditional common law elements of reliance and causation. The statute clearly requires, in a private action, that a plaintiff suffer an ascertainable loss as a result of the defendant’s prohibited action. Id. at 617-18, 777 A.2d 442 (emphasis in original). Clearly, Plaintiffs cannot use the fraud on the market theory to circumvent the reliance element of the UTPCPL. The suggestion that Defendants’ failure to advertise potential side of effects of Celebrex and Vioxx boosted sales and caused price inflation is an attempt to do just that, and as such must fail. 7 B. Learned Intermediary Doctrine 1. Implied Warranty of Merchantability In Makripodis v. Merrell-Dow Pharmaceuticals, Inc., 361 Pa.Super. 589, 523 A.2d 374 (1987), the Superior Court of Pennsylvania addressed the question of whether a retail druggist who filled a prescription “with the proper and unadulterated drug prescribed,” was “liable to the patient purchaser for breach of an implied warranty of merchantability if the drug caused harmful side effects.” Id. at 592, 523 A.2d 374. The court found that he was not, and that As heretofore observed, [prescription] drugs are not available to the general public and but may be obtained only upon the prescription of a licensed physician. This restriction upon the availability of such drugs has been imposed because of the inherently dangerous properties of such drugs. Prescription drugs may pose a threat to the safety of certain identifiable segments of the public, or may be dangerous when used in conjunction with other drugs or substances, or may be harmful if taken by *382 persons suffering from certain diseases or conditions. Id. at 594, 523 A.2d 374. (emphasis supplied). The court’s holding in Makripodis was based on Pennsylvania’s adoption of the learned intermediary doctrine. That rule, articulated by the Supreme Court in Incollingo v. Ewing, 444 Pa. 263, 288, 444 Pa. 299, 282 A.2d 206 (1971), was formulated “with reference to comment k [of the Restatement (Second) of Torts § 402A] and the policies expressed therein.” Coyle v. Richardson-Merrell, Inc., 526 Pa. 208, 213, 584 A.2d 1383 (1991). 8 It addresses the nature of a drug manufacturer’s duty to warn of potentially dangerous side effects and provides that when a drug “is available only upon prescription of a duly licensed physician, the warning required is not to the general public or to the patient, but to the prescribing doctor.” Baldino v. Castagna, 505 Pa. 239, 244, 478 A.2d 807 (1984). This is so “because it is the duty of the prescribing physician to be fully aware of the (1) the characteristics of the drug he is prescribing, (2) the amount of the drug which can be safely administered, and (3) the different medications the patient is taking. It is also the duty of the prescribing physician to advise the patient of any dangers or side effects associated with the use of the drug as well as how and when to take the drug.” Makripodis, 361 Pa.Super. at 596, 523 A.2d 374. Moreover, warnings are directed to the physician rather than the patient-consumer because “[i]t is for the prescribing physician to use his own independent medical judgment, taking into account the data supplied to him from the drug manufacturer, other medical literature, and any other source available to him, and weighing that knowledge against the personal medical history of his patient, whether to prescribe a given drug.” Leibowitz v. Ortho Pharmaceutical Corp., 224 Pa.Super. 418, 431, 307 A.2d 449 (1973). Hence, the “learned intermediary” stands between nearly every prescription drug manufacturer and the patient-consumer. For this reason, its application has been expanded to claims sounding in causes of action other than negligence. Recognizing this, the Makri-podis court held that the very nature of prescription drugs themselves precludes the imposition of a warranty of fitness for “ordinary purposes,” as each individual for whom they are prescribed is a unique organism who must be examined by a physician who is aware of the nature of the patient’s condition as well as the medical history of the patient. Makripodis, 361 Pa.Super. at 594, 523 A.2d 374. Makripodis, which involved a pharmacist, has subsequently been applied to claims against a manufacturer of prescription drugs, see Lennon v. Wyeth-Ayerst Laboratories, Inc., 2001 WL 755944 (Pa.Super.2001); Luke v. American Home Products Corp., 1998 WL 1781624 (Pa.Com.Pl.1998); and the makers of prescription medical devices, see Rosci v. AcroMed, *383 Inc., 447 Pa.Super. 403, 422-424, 669 A.2d 959 (1995). From the foregoing it is clear that manufacturers have duty to warn doctors of potentially dangerous side effects, and can be held liable for their failure to exercise reasonable care in doing so. While Plaintiffs here contend that Defendants “downplayed” or “failed to disclose” known cardiovascular risks posed by Celebrex and Vioxx, they do not (and, indeed, can not) couch their argument as one arising from a negligent failure to warn. Even if they were to do so, the argument would still fail. It is clear, under Pennsylvania law, that “the information supplied by the drug manufacturer is only one source a physician must consult, and he is expected to make an independent medical judgment in determining whether a given drug is appropriate for a particular patient.” Brecher v. Cutler, 396 Pa.Super. 211, 218-20, 578 A.2d 481 (1990) (emphasis supplied). Neither is a prescription drug manufacturer’s failure to warn actionable “where the prescribing physician did not rely on the package insert, has full information from other sources, and made his own independent medical judgment to prescribe it.” Leibowitz, 224 Pa.Super. at 432 n. 3, 307 A.2d 449; Stottlemire v. Cawood, 213 F.Supp. 897 (D.D.C.1963). The information that Plaintiffs claim the Defendants downplayed (or did not readily disclose) was contained in the results of published, presumably peer reviewed studies. The record before this Court establishes that Dr. Leventhal, the Plaintiffs’ treating physician, first learned of Cele-brex through medical meetings and literature even before its approval by the FDA, and that he had stayed abreast of the scientific literature analyzing the potential risks posed by COX-2’s. It further establishes that Merck released the results of the VIGOR study, comparing patients taking Vioxx to those taking a traditional NSAID, on March 23, 2000. Dr. Leven-thal testified that he read the VIGOR study when it was published in the New England Journal of Medicine in November of 2000. Dr. Leventhal also testified that he read an article in the Journal of the American Medical Association in August of 2000 which purported to analyze the combined results of different studies of Cele-brex and Vioxx. He asserted that the study referred to in the JAMA article was “extremely flawed,” and “used a control group from a completely different study which is not considered scientifically sound.” Based on the available information and data analyzing the risk of cardiovascular events associated with COX-2 inhibitors, Dr. Leventhal “did not feel that there was evidence ... that convinced [him] that there was an increased risk of myocardial infarction or thrombal embolic phenomenon with the COX-2’s” and therefore saw no reason to stop prescribing Celebrex or Vioxx to his patients. Dr. Leventhal did not rely on advertising to physicians or to the public when he determined that Celebrex and Vioxx were appropriate treatments for Heindel and Kin-month, but he did consider sources such as the FDA approved package insert, the Physician’s Desk Reference, and his own clinical experiences. In short, it is clear that Dr. Leventhal (1) based his decision to prescribe Cele-brex and Vioxx on information from a variety of sources and (2) that he certainly did not rely exclusively on information provided by the Defendants. For these reasons, as well as those discussed at length above, Defendants are entitled to summary judgment on Plaintiffs’ implied warranty claim. 2. Claims arising under the Unfair Trade Practices and Consumer Protection Law For reasons similar to those adduced above, Defendants are entitled to *384 summary judgment on Plaintiffs’ consumer fraud claims. The Court turns briefly to the particular application of the learned intermediary doctrine to claims arising under the UTPCPL. Plaintiffs claim that the Defendants knew of cardiovascular risks posed by Ce-lebrex and Vioxx, but spent “millions of dollars on direct-to-consumer advertising that portrayed these drugs as safer than other available treatments while uniformly omitting to disclose any risk of cardiovascular harm.” PL’s Opp. Br. at 1; Complaint at ¶¶ 2, 21-24, 36, 42-44, 51, 67. This “deceptive marketing scheme” caused their alleged economic injury and, they claim, violated the UTPCPL. 9 Defendants claim that Plaintiffs’ UTPCPL claim is barred by the learned intermediary doctrine. For several reasons, the Court finds that Plaintiffs’ claims are indeed barred by the learned intermediary doctrine. First, since the manufacturer of prescription drugs need only direct information and warnings to prescribing physicians, there “can be no cause of action based on Defendants’ alleged omissions because [they] had no duty to disclose any information to the plaintiff[s].” Albertson v. Wyeth, Inc. 2003 WL 21544488 at *12 (Pa.Com.Pl.2003); Luke v. American Home Products, 1998 WL 1781624 at *8 (Pa.Com.Pl.1998). Second, “to permit a cause of action under the UTPCPL in this case would effectively make a drug manufacturer the absolute guarantor of the anticipated results and effects of a prescription drug. Pennsylvania law, however, recognizes that some prescription drugs by their nature can never be made safe.” See Makripodis, 361 Pa.Super. 589, 523 A.2d 374; Luke, 1998 WL 1781624 at *8. Third, both the learned intermediary doctrine and the record before the Court establish that the Plaintiffs did not rely on any representations (or misrepresentations) by Defendants, and reliance is, of course, a necessary element of a UTPCPL claim. First, Heindel and Kinmonth both testified that they took Celebrex and Vioxx based on the advice of their treating physician. Kinmonth testified that she did not read information about Vioxx or material provided with Vioxx prior to taking it, and that she relied her on her physician’s advice regarding whether or not to take it. Heindel’s testimony also reveals that she relied on her doctor’s professional advice, rather than information supplied by Defendants, regarding Celebrex. She claimed not to have read any print advertisements for Celebrex, and though she said she had seen Celebrex television commercials, she asserted that she was not influenced by them. However, even if Heindel and Kin-month had offered evidence indicating that they had relied in some way on Defendants’ misrepresentations, it would ultimately be of no consequence. The learned intermediary breaks the chain in terms of reliance, since the patient cannot obtain prescription drugs without the physician no matter what they believe about them. Finally, the economic loss doctrine further mandates the entry of summary judgment dismissing Plaintiffs’ consumer fraud claims. Pennsylvania has adopted the economic loss doctrine, 10 as well as its *385 mirror image, the “gist of the action doctrine,” in order to “place a check on limitless liability for manufacturers and establish clear boundaries between tort and contract law.” Werwinski v. Ford Motor Co., 286 F.3d 661, 680 (3d Cir.2002). The parties have spilled a great deal of ink debating whether, under the UTPCPL, there is an “intentional tort” exception that would allow the plaintiffs to recover in tort for purely economic losses. Defendants contend that there is not, relying on the Third Circuit’s decision, in Werwinski, to “reject[ ] ... an intentional fraud exception” to the economic loss doctrine. Relying on O’Keefe v. Mercedes-Benz USA, LLC, 214 F.R.D. 266 (E.D.Pa.2003) (in addition to some Pennsylvania cases decided both before and after Werwinski), Plaintiffs argue that the economic loss doctrine has not been extended to cover intentional torts. The Supreme Court of Pennsylvania has not decided this question, and the lower Pennsylvania appellate courts are not in agreement on the matter. However, the job of this Court is greatly simplified by the Third Circuit’s exhaustive treatment of this issue in Werwinski, in which the Court upheld a district court’s prediction as to how the Pennsylvania Supreme Court would rule on this question. In doing so, the Court of Appeals explained that The district court applied the economic loss doctrine to the fraudulent eoncealment claims after recognizing the willingness of Pennsylvania courts to restrict intentional tort claims that overlap with contract claims. In the absence of any pertinent ease law on the subject, the district court aptly predicted that the Supreme Court of Pennsylvania would apply the economic loss doctrine to intentional fraud cases by drawing an analogy from Pennsylvania’s acceptance of the “gist of the action” doctrine. Such a conclusion is congruent with our past recognition that Pennsylvania state courts have exhibited a “lack of hospitality to tort liability for purely economic loss.” Werwinski 286 F.3d at 680. Moreover, the court held, “even if we were torn between two competing yet sensible interpretations of Pennsylvania law ... we should opt for the interpretation that restricts liability, rather than expands it, until the Supreme Court of Pennsylvania decides differently.” Id. (citations omitted). Consequently, the court held that there is no intentional fraud exception to the economic loss doctrine, whether the claim is one for common law fraud or arises under the UTPCPL. This Court is bound by the Third Circuit’s prediction of Pennsylvania law. Itzkoff v. F & G Realty of New Jersey Corp., 890 F.Supp. 351, 356 (D.N.J.1995). The decision of the district judge who decided O’Keefe, who clearly agreed with neither *386 the Third Circuit’s prediction nor the rationale upon which it rested, is not binding on this Court, and, since the Court of Appeals has predicted how the Pennsylvania Supreme Court will rule, the lower (Pennsylvania) courts’ decisions are also irrelevant for the purposes of this discussion. In short, this Court holds, pursuant to Werwinski, that economic loss doctrine bars Plaintiffs’ UTPCPL claim seeking recovery for their purely economic damages. C. Remaining Claims Plaintiffs’ claims for injunctive and equitable relief do not constitute separate causes of action. Accordingly, consideration by the Court of those claims would only be appropriate in the event that Plaintiffs had prevailed on their warranty and consumer fraud claims. Since they have not, the Court need not discuss the issue further. V. CONCLUSION For the foregoing reasons, Defendants are entitled to summary judgment dismissing Plaintiffs’ claims. An appropriate order will issue. Footnotes [1] Plaintiffs have also withdrawn several additional claims, which are therefore not addressed in this opinion. [2] Heindel and Dr. Leventhal testified that Heindel was prescribed and ingested Vioxx. However, Heindel has not made any claims against Defendant Merck & Co., the manufacturers of Vioxx. [3] Plaintiff's Complaint also contains claims under the New Jersey Product Liability Act (Count II) and for Medical Monitoring (Count V). See Complaint ¶¶ 83-91, 109-117. Plaintiffs agreed, in a consent order dated September 22, 2003, to dismiss their medical monitoring claim and to refrain from seeking certification of their products liability claim. Because they were not physically harmed by ingesting Celebrex and Vioxx and are not seeking damages for physical injury, Plaintiffs agreed, in a consent order signed April 28, 2004, to withdraw their individual products liability claims. Finally, Plaintiffs have acknowledged that their claim for injunctive relief is not a separate cause of action, and that accordingly consideration by the Court of that claim would be appropriate only in the event that Plaintiffs were to prevail on the breach of implied warranty and consumer fraud claims. [4] While Pennsylvania's requirement of a manifest defect or malfunction is slightly different than New Jersey’s more amorphous standard, which refers variously to "injury” and "defect,” this Court finds that there is no actual conflict between the laws of the two states. [5] For the purposes of this discussion, factors such as the number of people employed in New Jersey by the Defendants are not relevant, just as Defendants' filing of unrelated lawsuits in the District of New Jersey bears no relation to the inquiry at hand. [6] In fact, the Pennsylvania courts have even declined to abrogate the learned intermediary doctrine in cases involving direct to consumer marketing, holding that despite these practices the decision to take a particular drug is still dependant on the judgment of a physician. See Lennon v. Wyeth-Ayerst Laboratories, Inc., 2001 WL 755944 (Pa.Super.2001); Albertson v. Wyeth Inc., 2003 WL 21544488 (Pa.Com.Pl.2003). [7] Plaintiffs' claims would be similarly precluded under New Jersey law. In Kaufman v. i-Stat Corp., 165 N.J. 94, 754 A.2d 1188 (2000), the New Jersey Supreme Court rejected the use of the “fraud on the market” or "price inflation” theory to establish the causal nexus between the defendant’s alleged misrepresentations and their loss. While i-Stat considered the fraud on the market and price inflation theories only in the context of traditional common law fraud, where pleading and proving the element of reliance remains a part of plaintiff's burden, at least one other New Jersey court has concluded, relying on i- Stat’s reasoning, that those theories “have no place as a part of the proofs required of plaintiffs in the CFA [New Jersey Consumer Fraud Act] context either.” New Jersey Citizen Action v. Schering-Plough Corp., 361 N.J.Super. 8, 14-16, 842 A.2d 174 (2003). Allowing plaintiffs to rely on those theories, the court held in New Jersey Citizen Action, would "virtually eliminate the requirement that there be a connection between the misdeed complained of and the loss suffered. Adopting plaintiff’s theory ... would therefore fundamentally alter the concept of causation in the CFA context ... [and] the relationship between the alleged misstatement and the ascertainable loss suffered would become so attenuated that it would effectively disappear.” [8] Comment k addresses whether a manufacturer of products that are inherently unsafe, but accompanied by proper warnings (such as prescription drugs) should be held strictly liable for the "unfortunate consequences attending the use of otherwise useful and desirable products which are attended with a known but apparently reasonable risk,” and concludes that "such a manufacturer is liable only if he fails to exercise reasonable care to inform those for whose use the article is supplied of the facts which make it likely to be dangerous.” Though comment k specifically addresses the imposition on drug-makers of strict liability, (as opposed to liability for negligence) the learned intermediary doctrine arises from its broader point regarding the adequacy and intended recipients of drug warnings. [9] Plaintiffs brought their consumer fraud claim as one arising under the New Jersey Consumer Fraud Act and the consumer protection statutes of "other states." Though their pleadings and briefing focus on the New Jersey Consumer Fraud Act, they contend that the Pennsylvania law would require the same outcome. [10] New Jersey also recognizes the economic loss doctrine, although New Jersey courts have not addressed its application in a context similar to the one presented here. How *385 ever, in Alloway v. General Marine Indus., 149 N.J. 620, 627-630, 695 A.2d 264 (1997), the New Jersey Supreme Court found that contract remedies are better suited than tort law to resolve claims for economic loss, whether the sale at issue was characterized as a consumer purchase or a commercial transaction. It's decision rested on a finding that purchasers who fall victim to fraud or unconscionable conduct will have "substantial rights to recover for common law fraud and for violation of various state and federal statutes such as the New Jersey Consumer Fraud Act.” Boyes v. Greenwich Boat Works, Inc., 27 F.Supp.2d 543, 550 (D.N.J.1998). "In sum,” the Court concluded in Alloway, judicial decisions and statutory encasements, including the U.C.C., protect consumers from overreaching. Against this background, a tort cause of action for economic loss duplicating the one provided by the U.C.C. is superfluous and counterproductive. Alloway, 149 N.J. at 641, 695 A.2d 264.